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This-study evaluates the effects of the transfusion 
of frozen-thawed blood protected by hydroxyethyl 
starch (HES) on shocked monkeys. Particular at- 
tention is directed toward the study of coagula- 
tion in view of previous reports of coagulopathies 
caused by hydroxyethyl atarch. In vivo studies 
were done in 13 shocked monkey that received 
either homologous or autologous blood which had 
been f r o m  and thawed with 14 per cent HES aa 
the cryoprotective agent. Multiple coagulation stud- 
ies were obtained on the monkeys, and histopatho- 
logical evaluations were performed. There wa8 no 
evidence of increased bleeding or bleeding tendencies 
in the monkeys transfused with HES preserved 
blood. Serum chemistry values were not signifi- 
cantly altered in animals that received blood pre 
S C N ~  by HES nor in those that received large 
quantities of HES alone. Histopathological exam- 
ination of biopsy and autopsy material demon- 
strated no changes which could be related to hy- 
dmxyethyl starch. 
CRYOPROTECTIVE agents used in freeze 
preservation of whole blood can be di- 
vided into two major groups: those that 
protect by intracellular mechanisms and 
those that are primarily extracellular in 
action.18 The intracellular agents, glycerol 
been shown to produce a satisfactory de- 
gree of cryoprotection. These substances 
must be thoroughly removed postthaw by 
washing. Hydroxyethyl starch (HES) is a 
plasma expander similar to Dextran and 
PVP1. 5. 10, 14. 25 and is an extracellular cryo- 
protective agent.12 It is considered non- 
toxic20 6. 19 and nonallergenic.3.17 However, 
HES protected blood may be washed with- 
out adverse effects.11 
4, 7. 9, 13, 20. 22. 23. 24 and DMS0,8, 16 have 
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This paper describes coagulation studies 
performed upon shocked monkeys trans- 
fused with the frozen-thawed blood pro- 
tected by low molecular weight HES. Cer- 
tain authorslo- 14, 27 have reported altera- 
tions in coagulation mechanisms during 
the administration of hydroxyethyl starch 
of high molecular weight (200,000 or 
greater). Studies were done on the blood 
of two monkeys infused with large amounts 
of 12 per cent HES solution alone. We 
have shown (unpublished data) that the 
degree of protection afforded the erythro- 
cytes by “low” molecular weight starch was 
equal to or slightly better than that of 
the high molecular weight (plasma ex- 
pander type) HES. The inherent viscosity 
of the high molecular weight material was 
higher (O.Sdl/g) than the 0.15dI/g viscosity 
of the low molecular weight starch. The 
degree of substitution was the same how- 
ever, in the range of 0.7 = 0.8DS. The 
degree of substitution is directly related to 
the rate of degradation in the blood 
stream.10 
Methods 
Thirteen monkeys were anesthetized and the 
femoral artery and vein were cannulated with 
polyethylene catheters connected to a Sanborn 
multichannel recorder which monitored arterial 
and venous pressure. Blood equal to 30 to 50 
per cent of the blood volume was removed 
from each monkey in order to lower the sys- 
tolic pressure to at least 60 mm of mercury at 
which point the monkeys had tachycardia and 
tachypnea. The  amount of blood and HES 
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animals. I n  general, the volume replaced 
equalled the amount withdrawn (k., 30 to 50 
per cent of the calculated blood volume.) I n  
the blood transfused, there was 14 per cent 
hydroxyethyl starch by weight. This  quantity 
of hydroxethyl starch was somewhat greater 
than that used in  previous studies with HES as 
a volume expander.10 T h e  HES percentage 
was obtained by adding 35 ml of a 40 per cent 
solution of the starch in normal saline to 65 
ml whole blood and the resultant hematocrit 
levels were in  the range of 20 to 27 per cent. 
T h e  blood with HES was prepa:.ed i n  55 ml 
aliquots. Seven monkeys received homologous 
blood previously frozen with 14 per cent hydro- 
xyethyl starch solution. T h e  blood-HES mix- 
ture was transfused after thawing without 
washing. Six monkeys were transfused with 
autologous blood withdrawn during the experi- 
ment in sterile ACD vacuum bottles, processed 
with HES, frozen in liquid nitrogen, and 
thawed while the animal was in  the shocked 
state. 
Kidney and liver biopsy specimens were 
obtained before and after the transfusions with 
HES. T h e  lower molecular weight HES used 
in these studies had a molecular weight of 
28,000 to 45,000. Four animals used as histo- 
pathological controls were exsanguinated, their 
blood frozen for homologous transfusions, and 
the animals were autopsied. Sections of kidney, 
lung, lymph nodes, spleen, and liver were exam- 
ined. Formalin and alcohol fixed tissues were 
stained with hematoxylin and eosin and with 
periodic acid-Schiff (PAS) with and without 
diastase digestion. T h e  rationale for using PAS 
stain with alcohol fixation to locate HES was 
based on  the work by Mowry and Millicanzl 
who used the method to demoristrate Dextran 
in mouse tissues. 
Whole blood hemoglohin, plasma hemo- 
globin, hematocrit, per cent red blood cell re- 
covery, red cell saline stability, and potassium 
levels were determined for each aliquot of 
monkey donor blood prior to transfusion. 
Renal function studies (serum creatinine, 
blood urea nitrogen, and urinalysis) were done 
for all animals prior to shock, one hour after 
transfusion and at  intervals u p  to 48 hours. 
Coagulation studies were done prior to shock, 
during the shock phase, at one hour, 24 and 48 
hours posttransfusion. T h e  studies obtained 
were: a platelet count utilizing phase micro- 
scopy, quantitative fibrinogen by tyrosine assay, 
total protein, one stage prothrombin time, par- 
tial thromboplastin time (PTT)  , thrombin 
clotting time (TCT), and euglobulin lysis. Ex- 
cept for the platelet counts, these were done on 
frozen thawed plasma. In addition, thrombin 
clotting times and euglobulin lysis times were 
obtained on  fresh blood. 
To further study changes in coagulation 
caused by hydroxyethyl starch itself, two ani- 
mals were bled of 1/4 to 1/3  of their estimated 
blood kolumes. While these two monkeys were 
in the shocked state, a n  amount of 12 per cent 
HES in saline equal to the amount of blood 
removed was infused. I n  these animals, pro- 
tlirombin consumption tests and platelet factor 
I11 assays were obtained as well as those tests 
listed above. 
Results 
Table 1 shows coagulation data obtained 
from the monkeys in  shock transfused with 
HES-preserved blood. This  table includes both 
the homologous and autologous blood transfu- 
sions as there appeared to be no difference in  
the values obtained. T h e  pretransfusion data 
was obtained while the monkey was in  shock 
just prior to the administration of the HES pre- 
served blood. There was a lowering of the 
mean fibrinogen level one hour after transfu- 
sion with a return to high levels a t  24 hours. 
T h e  platelet counts showed a mild decrease. 
In  one monkey, platelets decreased to 70,000/ 
mm3 pretransfusion and in  one at  24 hours the 
platelet count was 92,000/mm.3 Prolongation 
of the prothrombin time was noted at  one hour 
after transfusion with a return to normal in  24 
hours. T h e  decrease in the total protein ap- 
peared to be of the same magnitude as the 
degree of lowering seen in the fibrinogen 
assays. At one hour posttransfusion, the P T T  
alppeared slightly prolonged and all returned 
to normal a t  24 hours. Thrombin clotting time 
was normal or  shortened in  seven of I3 monkeys 
at one hour posttransfusion. In  the other six 
monkeys, prolonged TCT’s were seen. I n  the 
monkeys with the prolonged T C T ,  the partial 
thromboplastin time and one stage prothrom- 
bin time were also prolonged. Euglobulin lysis 
time showed insignificant shortening in about 
half of the monkeys. Only one monkey had a 
lysis time of 30 minutes a t  24 hours postinfu- 
sion. This  monkey did not show any evidence 
of increased bleeding tendency. At 48 hours, 
all evidence of increased euglobulin lysis had 
disappeared. 
Table  2 lists the results of studies obtained 
after transfusing two monkeys with a 12 per 
cent solution of low molecular weight HES to 
replace an amount equivalent to approximately 
114 or  I / 3  of their blood volume. T h e  pro- 
thrombin consumption studies are within nor- 
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TABLE 1 .  Coagulation Studies in 13 Shorked Monkeys Transfused with Hes-Preserved Blood 
Test 
Posttransfusion Posttransfusion 
Preshock Pretransfusion 1 Hour 20-24 Hours 
~ ~ ~~ ~ 
Fibrinogen 374* 318 214 413 
Platelets 465 348 254 297 
(mg/lOO ml) (265-590)t (28S590) (155-390) (276-576) 
10s mm* (320-@0) (70-560) (150-405) (92-505) 
One-stage 
prothrombin 11.4 11.3 16.7 11.7 
time (sec) (9.6-14.0) (10.8-16.0) (1 1-27) (10-14) 
Total 
protein 6.4 5.4 4.0 5.5 
(l3/100 ml) (5.47.6) (4.8-6.3) (3.2-5.3) (4.3-6.2) 
PTT 42 46 56 39 
(28-59) (3263) (49-67) (33-54) 
(180 sec. for 
1 monkey) 
TCT 31 37 (1645) 29 
(20-53) (18-63) (in 7 monkeys) (16-52) 
(48-180) 
(in 6 monkeys) 
Mean. 
t Range. 
nial limits. A dilutional effect with a mild de- 
crease in total protein and fibrinogen, and a 
slight prolongation of the one stage prothrom- 
bin time and the PTT were noted. No changes 
were noted in thrombin clotting time or euglo- 
bulin lysis. 
Table  3 lists the mean values of studies done 
on animals that received autologous transfu- 
sions and Table  4 lists the mean values of 
studies done on monkeys receiving honiologous 
transfusions. These studies were obtained prior 
to shock, one hour posttransfusion and 20 
hours posttransfusion. T h e  blood was trans- 
fused without postthaw washing, and there was 
a mean elevation u p  to 85 mg/100 ml in the 
plasma hemoglobin in the aninials receiving 
autologous blood and 206 mg/100 ml in the 
group receiving homologous blood. Infusion of 
blood frozen with any cryoprotective agent will 
result in postthaw levels of plasma hemoglobin 
ranging from 200 to 900 mg/100 ml.13. 23 This  
hemoglobin may be reduced by postthaw wash- 
ing before transfusion to levels in  the range 
of 100 to 200 mg/100 ml or less.22 No hemo- 
globinuria was noted in either group. T h e  
creatinine levels were elevated temporarily and 
the serum potassium was essentially unchanged. 
Blood urea nitrogen was elevated minimally a t  
48 hours in  both groups. However, a t  the end 
of four days, all values had returned to normal. 
Histopathological studies in  the four control 
animals disclosed rather extensive preexisting 
disease. All of them had birefringent particles. 
possibly silica, in  the lungs and two of them 
had acute pneumonia. In another animal, liver 
necrosis was noted as well as PAS positive ma- 
terial in spleen, liver, and lymph nodes with 
and without diastase digestion with formalin 
fixed tissues. No other significant findings were 
noted except for occasional phagocytes which 
contained PAS positive material. Biopsies of 
liver and kidney from preshock test monkeys 
were also used as controls. 
Liver and kidney biopsies were obtained 
after transfusion at  various times on six of the 
test animals that received homologous blood 
HES transfusion and no consistent differences 
were noted between controls and test animals. 
Discussion 
The coagulation data obtained on the 
shocked monkeys given blood preserved 
with hydroxyethyl starch revealed no con- 
sistent or significant difference between 
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TABLE 2. Coagulation Studies in Two Monkeys Given 12 Per Cent Hes Replacing 
to $” of Their  Blood Volume 
Control+ Postinfusion Postinfusion Postinfusion 





































































































+ Previously established from ten normal monkeys. 
homologous and autologous blood transfu- 
sion. The lowering of the total protein, 
fibrinogen and platelets is consistent with 
dilution; there was some increase in the 
mean fibrinogen at 48 hours. Others have 
observed similar coagulation changes fol- 
lowing Dextran and high molecular weight 
hydroxyethyl starch infusion.ls 
TABLE 3. Results of Tests Obtained on Six Monkeys Receiving Autologoris Transfusions 
Posttransfusion Posttransfusion Posttransfusion 
Test Preshock 1 Hour 20 Hours 48 Hours 
Blood urea 
Nitrogen 16. 21 28 31 
(ms/ 100 ml) ( 12-20)t (1 626)  (17-48) (27-44) 
Creatinine 
(mg/100 ml) 1.2 1.5 1.6 1.3 
(O.Sl.4) (0.9-1.9) (1 .l-1.8) (1 .o-1.5) 
4.7 45 4.8 4.6 
(4.0-5.1) (3.54.9) (3.7-5.2) (4.3-4.7) 
Plasma 
hemoglobin 10.8 85 32.2 10 
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TABLE 4. Results of Tests on Seven Monkrys Receiving Homologous Transfusions 
Posttransfusion Posttransfusion Posttransfusion 
Test Preshock 1 Hour 20 Hours 48 Hours 
Blood urea 
Nitrogen 20' 24 30 10 
(mg/ 100 ml) (14-34)t ( 19-37) (21-38) (1541) 
Creatinine 1.4 1.4 1.7 1.4 
(mg/100 ml) (1.2-1.8) (0.9-2.0) (1 4-2.2) (1.2-1.5) 
3.4 3.6 4.3 4.1 
(3.0-3.7) (2.6-5.2) (3.24.4) (3.4-5 .O) 
Plasma 
hemoglobin 14.8 206 34.6 175 
(mg/100 ml) (6-22) (92-362) (12.9-52) (10.2-27.4) 
Mean. 
t Range. 
In  the two monkeys given 12 per cent 
HES solution to replace their blood vol- 
ume, no abnormality was observed in plate- 
let factor 111. We did not study the pro- 
thrombin consumption at  four or  eight 
hours posttransfusion, and i t  is possible 
that some platelet abnormalities could have 
been present at  that time. However, none 
of the monkeys demonstrated any bleed- 
ing tendency or  wound oozing. T h e  reason 
for prolongation of T C T  in some animals 
is not clear. The  HES may interfere 
with thrombin fibrinogen interaction. This 
could explain the prolongation of some of 
these coagulation tests in our shocked ani- 
mals. The  action on the coagulation mech- 
anisms may depend upon the concentration 
of the HES present in the blood. There 
was no evidence of heparinoid action by 
this agent and abnormalities were not cor- 
rected by the addition of protamine in 
vitro. 
In  similar experiments using polyvinyl 
pyrrolidone as the cryoprotective mate- 
rial,26 we observed hemoglobinuria that 
persisted for the first 24 hours. I n  the ani- 
mals gives the HES-blood mixture, no 
hemoglobinuria was detected in any of the 
monkeys. 
Creatinine levels were elevated as noted 
at one and 20 hours but returned to nor- 
mal levels within 48 hours. Acute renal 
damage did not occur. T h e  modest eleva- 
tion of the blood urea nitrogen can be 
attributed to hypovolemic induced changes 
in the animals. The  elevations were not 
striking and were temporary. Similarly, 
serum potassium levels were not changed 
significantly. As expected, an elevation of 
plasma hemoglobin occurred one hour 
after transfusion. Within 24 hours, this 
had decreased and at 48 hours it had re- 
turned to preshock levels. T h e  plasma 
hemoglobin levels were highest in the ani- 
mals receiving homologous blood. We did 
not do compatibility studies for these trans- 
fusions. 
I t  is difficult to evaluate the tissue 
change seen because of the variability of 
the findings. For example, liver necrosis 
was present in controls as well as test ani- 
mals. T w o  animals died rather acutely, 
one because of fluid overload and the sec- 
ond because of insufficient blood replace- 
ment. Two other monkeys were sacrificed. 
PAS positive material was inconstantly seen 
in macrophages and epithelial cells in liver, 
spleen, and kidney in both control and test 
animals. 
Mowry and Millican21 have demonstrated 
PAS positive material in various organs 
after Uextran infusion up to three months 
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following transfusion. In this study, PAS 
postive material was noted in macrophages 
in both control material and test animals 
so there was no evidence that HES of low 
molecular weight persists in tissues. There 
was no consistent histopathological changes 
that could be related to the presence of 
HES in the blood transfused. 
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THE NATIONAL Heart and Lung Institute 
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ing in basic biomedical sciences and research 
in  clinical specialties related to certain areas 
of programmatic interest as identified in the 
National Heart, Blood Vessel, Lung and Blood 
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In addition to supporting fellowship awards 
i n  heart, vascular and lung diseases, the Bureau 
seeks particularly to  support individual fellow- 
ship awards in  the areas of hemophilia and 
clotting proteins, thrombosis (thromboembolic 
disorders, microcirculatory thrombosis), plate- 
lets, hemocompatible materials, hemoglobin 
and hemoglobinopathies, RBC enzymes and 
membranes, transplantation biology, blood 
banking sciences (blood factionation and p r e s  
ervation. hepatitis, blood safety, immunohema- 
tology) and artificial blood. 
I n  the broad area of blood clotting abnor- 
malities, there is particular interest in  hemo- 
philia, plasma clotting and lysing proteins, 
genetic control mechanisms, platelet structure, 
function and regulation, the role of microcir- 
culatory thrombosis and methods of this study, 
the relation of thrombosis to  atherosclerosis and 
the basic mechanisms involved in  the process 
of thrombosis. Closely related to this are studies 
concerned with the interaction between blood 
components and synthetic surfaces a t  a molec- 
ular level. 
Individual copies are available on request. 
Of the many aspects of red cell research, 
hemoglobins and hemoglobinopathies are con- 
sidered target areas. T h e  molecular aspects of 
hemoglobin structure, function and regulation 
are of particular interest. Further research also 
is needed in red cell enzyme systems and red 
cell membrane structure and function. 
Blood banking science also is a major target 
area. I n  addition to basic studies of mecha- 
nisms involved in preservation of cellular ele- 
ments, research into fractionation techniques, 
transfusion related hepatitis, and immunohema- 
tology require additional impetus. 
I n  the related area of transportation biology, 
the Institute will support research training in  
immunogenetics, organ preservation and the 
pathophysiology of the posttransplant state. 
Applications will be reviewed and awards ad- 
ministered in  accordance with the information 
presented in  the N I H  Guide for Grants and 
Contracts, Volume 2, No. 10, November 30, 
1973. Deadline for receipt of applications is 
May 1, 1974. Application material may be 
obtained from the Office of Research Man- 
power, Division of Research Grants, National 
Institutes of Health, Bethesda, Maryland 20014. 
For further information regarding programs of 
the Division, contact: 
Dr. Harvey Klein 
Division of Blood Diseases and Resources 
Building 31, Room 4A-04 
National Heart and Lung Institute 
National Institutes of Health 
Bethesda, Maryland 20014 
